Sector News

Nicholas Valeriani Appointed To Edwards Lifesciences’ Board Of Directors

November 17, 2014
Life sciences
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee.  Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs.  Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee. 
 
“We are pleased to add Nick’s talents and deep experience to a strong board that is guiding Edwards’ focused innovation strategy, as we develop and deliver important therapies to patients in need,” said Michael A. Mussallem, Edwards’ chairman and CEO. “I’m confident that his long career dedicated to improving patients’ lives provides him with a very informed and contemporary view on both the development of groundbreaking devices and also how best to provide them to patients and physicians in an increasingly complex global healthcare system.”
 
Currently, Valeriani serves on the boards of directors of Robert Wood Johnson University Hospital, the Reagan-Udall Foundation, Reflexion Health, Inc., and the Center for Medical Interoperability.
 
Valeriani has a master’s degree in business administration from Rutgers University, Graduate School of Management, and a bachelor’s degree in industrial engineering from Rutgers University, College of Engineering.
 
Source: Edwards Lifesciences

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend